Yes, Sprycel Treats Specific Cancers
Sprycel (dasatinib) is a targeted cancer drug approved by the FDA for treating chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It inhibits BCR-ABL tyrosine kinase, a protein driving these blood cancers.[1]
How Sprycel Works in Cancer Cells
Sprycel blocks enzymes that cause uncontrolled growth in CML and Ph+ ALL cells. It's used in chronic, accelerated, or blast-phase CML, often after other treatments like imatinib fail, and for adults with Ph+ ALL in combination therapy.[1][2]
Approved Uses and Patient Groups
- Newly diagnosed chronic-phase CML adults.
- CML resistant or intolerant to prior therapies.
- Chronic-phase CML in children aged 1+.
- Ph+ ALL in adults with other treatments.[1]
It's taken orally as tablets, with dosing based on phase and response.
Common Side Effects Patients Report
Patients experience low blood cell counts, fluid retention, diarrhea, headache, fatigue, and rash. Serious risks include heart issues, bleeding, and pulmonary hypertension. Monitoring is required during treatment.[1][2]
Who Makes Sprycel and Patent Status
Bristol Myers Squibb manufactures Sprycel. U.S. patents have faced challenges; key ones expired around 2025-2026, opening doors for generics. Check DrugPatentWatch.com for latest expiry dates and litigation.[3]
Alternatives and Comparisons
Imatinib (Gleevec) is a first-line CML option; bosutinib or ponatinib for resistant cases. Sprycel often works better in some imatinib failures due to broader kinase inhibition.[2]
Sources
[1]: FDA Label for Sprycel
[2]: NCCN Guidelines for CML
[3]: DrugPatentWatch.com - Sprycel Patents